Scienture Holdings, Inc. (SCNX)
$3.76-2.59%Close
SELLCRISIS · day 33
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $58M
- Beta
- 3.98
- P/E (TTM)
- -0.08
- Short % float
- 16.47%
- Days to cover
- 1.0
- SI change
- +4.3%
- 1W
- -5.29%
- 1M
- -57.94%
- vs SPY 1W
- -6.45%
- vs SPY 1M
- -60.93%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 14
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-32.1%
REV YoY-
ROE-53.5%
EPS YoY-
ROA-43.3%
GROSS31
OP-1671
NET-4621
[VALUATION]
P/E TTM-0.08
P/E FWD-
SECTOR PE20.47
INDUSTRY PE108.47
P/B0.09
P/FCF-
EV/EBITDA-0.24
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E16.68
ALTMAN Z-
CURR RATIO3.04
ND/EBITDA-
BETA3.98
Company news
FAQ
- What is LOPJLB’s current signal on SCNX?
- LOPJLB’s latest quantitative signal on Scienture Holdings, Inc. (SCNX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SCNX in?
- Scienture Holdings, Inc. (SCNX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Scienture Holdings, Inc. (SCNX) do?
- Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk …